Peptide library / Digestive & weight / Lutetium Lu-177 dotatate
Lutetium Lu-177 dotatate
A radioactive peptide that delivers radiation directly to neuroendocrine tumors.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Gastroenteropancreatic neuroendocrine tumorsFDA approved
How it is thought to work
The peptide part binds somatostatin receptors on tumor cells and carries a radioactive lutetium atom that destroys them from inside.
What the evidence shows
The NETTER-1 trial showed much longer progression-free survival than high-dose octreotide.
Safety and unknowns
Nausea, low blood counts and, rarely, kidney effects or blood cancers.
Regulatory status
FDA-approved as Lutathera in 2018.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
Maridebart cafraglutide
In clinical trialsAn investigational monthly injection that pairs a GLP-1 agonist with an antibody that blocks the GIP receptor.
Mazdutide
In clinical trialsA dual GLP-1 and glucagon receptor agonist developed by Innovent, approved in China for obesity.
Lixisenatide
FDA-approvedA short-acting GLP-1 receptor agonist taken once daily, no longer sold in the United States.
General information, not medical advice. Do not buy or inject unregulated peptides.